LCT expands diabetes trial
Friday, 06 June, 2008
Living Cell Technologies (ASX: LCT) has decided to begin testing larger doses in its phase 1 clinical trial for type 1 diabetes.
In phase one of the trial, five patients were implanted with the lowest recommended dose of the company's DiabeCells, encapsulated insulin-producing cells sourced from pigs.
So far the patients have experienced no ill-effects, and have experienced a quantifiable reduction in the amount of insulin they require daily.
Both the number of patients and the dosage they receive has been doubled over the previous trial, with 10 patients receiving the double dose.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
